Modality
ADC
MOA
WRNi
Target
KRASG12C
Pathway
Amyloid
NBFTDMyelofibrosis
Development Pipeline
Preclinical
~May 2015
→ ~Aug 2016
Phase 1
~Nov 2016
→ ~Feb 2018
Phase 2
~May 2018
→ ~Aug 2019
Phase 3
~Nov 2019
→ ~Feb 2021
NDA/BLA
~May 2021
→ ~Aug 2022
Approved
Nov 2022
→ Jun 2029
ApprovedCurrent
NCT07807439
750 pts·FTD
2022-11→2029-06·Recruiting
NCT08751608
1,901 pts·NB
2025-03→TBD·Not yet recruiting
NCT08838499
845 pts·FTD
2025-12→2027-10·Recruiting
+1 more trial
5,112 total pts2 indications
CompletedCurrentUpcoming
Catalysts (3)
2026-01-202mo agoPh3 Readout· NB
2027-10-091.5y awayPh3 Readout· FTD
2029-06-043.2y awayPh3 Readout· FTD
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
Approved
Recruit…
Approved
Recruit…
Approved
Not yet…
Approved
Recruit…
Catalysts
Ph3 Readout
2026-01-20 · 2mo ago
NB
Ph3 Readout
2027-10-09 · 1.5y away
FTD
Ph3 Readout
2029-06-04 · 3.2y away
FTD
RecruitingNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07807439 | Approved | FTD | Recruiting | 750 | CR |
| NCT08751608 | Approved | NB | Not yet recr... | 1901 | SeizFreq |
| NCT08838499 | Approved | FTD | Recruiting | 845 | Safety |
| NCT08385295 | Approved | NB | Recruiting | 1616 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C |